Back to search results

Imaging and Diagnostic Assessments for Tauopathies

This study, called CW2IP2, is looking at different ways to diagnose conditions like Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Frontotemporal Dementia (FTD), which are all types of tauopathies (diseases where certain proteins build up in the brain). Researchers are using brain MRI scans and neurologic exams (tests of your brain and nerve function, including a video interview) to gather information. The goal is to collect key data to help develop new "radiotracers" (special substances used in imaging tests) that can specifically identify certain compounds in the brain. The study aims to determine a disease diagnosis within 8 weeks. It is open to men and women aged 40 to 85 years old. The study is currently recruiting up to 94 participants across multiple sites.

Study design
This is an interventional study involving up to 94 participants. It is a multi-site study centered at U Pennsylvania, with collaboration from U Pittsburgh, Yale University, UCSF, and Washington University in St. Louis.
What's involved
Participants will undergo a brain MRI scan and a neurologic exam, which includes assessments and a video interview. Some sites may also include PET imaging of A-beta amyloid.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for disease diagnosis is measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06083467

CW2IP2: Imaging and Diagnostic Assessments

Recruiting
NAAges 40–85InterventionalDiagnostic
University of Pennsylvania
~94 participants
Updated 2026-01-07 on ClinicalTrials.gov
What's tested:Brain MRI ScanNeurologic exam

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease diagnosis
Measured over 8 weeks

Conditions

Tauopathies

Explore related trials

Frontotemporal DementiaMultiple System AtrophyParkinson DiseaseProgressive Supranuclear Palsy

Where it's being run

1 sites across 1 states
Pennsylvania1

Who to contact

Erin o Schubert
[email protected]
2155736569
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants: Patients in all cohorts will range from 40 to 85 yrs and will be both male and female.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Participants who are deemed unable to provide informed consent must have a designated Legally Authorized Representative(LAR) present for consent and a Study Partner to accompany them to study visits. The LAR and the Study Partner may be the same person.
Clinical diagnoses for each cohort will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP, FTD or Healthy control)

Exclusion

Females who are pregnant or breast feeding at the time of screening will be excluded
Forms of parkinsonism other than PD, PSP and MSA as defined above
Major psychiatric disorder (e.g. schizophrenia or bipolar disorder)
History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported
Contraindications or Inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician
Implanted medical device or other contraindication to MRI
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study
Refusal to consent to brain donation (except for HC cohort). All non-HC participants must agree to postmortem brain donation..

What this trial measures

  • Disease diagnosis8 weeks

    The primary outcome is a diagnosis classification of a neurodegenerative disease. Participants will be referred based on a clinical evaluation suggesting possible Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Frontotemporal Lobar Degeneration, or other neurodegenerative disease or as a likely healthy control. Participants will have cognitive testing, physical examination, imaging studies, and record review, which will be used to determine the probable diagnosis. If no probable diagnosis is achieved, the outcome would be an uncertain diagnosis.